Azacitidine
Recurrent Non-Small Cell Lung Carcinoma
Albert Einstein College of MedicineSmall moleculePhase 2Dormant
BB
71/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 57/ 100
- Competitive Position
- 95/ 100
Competitive context
1206 Active assets in the Recurrent Non-Small Cell Lung Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Zorifertinib Alpha Biopharma (Jiangsu) Co., Ltd. | Phase 2/3 | BBB |
Necitumumab Jonsson Comprehensive Cancer Center | Phase 3 | BBB |
Glumetinib Shanghai JMT-Bio Inc. | Phase 3 | BBB |
Zoledronate Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 4 | BBB |
Onartuzumab Hoffmann-La Roche | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Azacitidine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
73 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →